Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Gabriela Hobbs

  • Home
  •  
  • Gabriela Hobbs



  • Most Read
  • Latest Comments
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

  • Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients
    • News

  • Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%
    • News

  • Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    Former Big Pharma VP takes helm of Syntara Board, accelerates cancer drug development
    • News

  • Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars
    • News

  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

    Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

    Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.